Product record

Gabapentin: batches declared Not of Standard Quality

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts, Jan 2019, Jul 2026

11 batches of products named "Gabapentin" (as printed by the testing lab) failed a CDSCO or state drug-testing laboratory test between January 2020 and May 2026. This is a record of specific batches, it does not mean the molecule or every brand is unsafe.

Records by type

11 records linked to Gabapentin in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
11Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jan 2020 to May 2026

View original document

Scope. A failed batch is not a verdict on every pack of this product. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

11
NSQ batches
8
Manufacturers
Labelling
Most common reason
May 2026
Latest alert

Flagged batches

Batch Manufacturer Reason declared NSQ Tested by Alert
TSF-DO897Mfg 2025-05 · Exp 2027-04 Spen Formulations Pvt. Ltd The sample does not conform to IP 2022 requirements w.r.t Dissolution TestDissolution DTL,Dalgate Srinagar kashmirState lab May 2026
LPC25029Mfg 2025-02 · Exp 2027-01 Levotic Pharma Description and Uniformity of WeightDescription SDTL, PunjabState lab Feb 2026
AFC2411056Mfg 2024-11 · Exp 2026-10 Alifecare FormulationHimachal Pradesh The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 65.02% of labelled claim against Q value of NLT 80% of labelled claim.Labelling State Drugs Laboratory, PunjabState lab Jul 2025
AFC2501028Mfg 2025-01 · Exp 2026-12 Alifecare FormulationHimachal Pradesh The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 68.50% of labelled claim against Q value of NLT 80% of labelled claim.Labelling State Drugs Laboratory, PunjabState lab Jul 2025
AFC2501029Mfg 2025-01 · Exp 2026-12 Alifecare FormulationHimachal Pradesh The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 68.88% of labelled claim against Q value of NLT 80% of labelled claim.Labelling State Drugs Laboratory, PunjabState lab Jul 2025
AFC2502059Mfg 2025-02 · Exp 2027-01 Alifecare FormulationHimachal Pradesh The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 71.22% of labelled claim against Q value of NLT 80% of labelled claim.Labelling State Drugs Laboratory, PunjabState lab Jul 2025
SG2412559Mfg 2024-12 · Exp 2026-11 Scout Lifescience Pvt. LtdHaryana Uniformity of WeightUniformity of weight/content State Drugs Laboratory, PunjabState lab May 2025
MT225040Mfg 2022-11 · Exp 2024-10 Mascot Health Series Pvt. LtdUttarakhand Related SubstancesRelated substances CDL KolkataCDSCO lab Apr 2024
22S1GTB467Mfg 2022-11 · Exp 2024-10 Synokem Pharmaceuticals LtdUttarakhand Related SubstancesRelated substances CDTL KolkataCDSCO lab Mar 2023
1721-625Mfg 2021-11 · Exp 2024-10 Zee Laboratories LtdHimachal Pradesh Related SubstancesRelated substances RDTL ChandigarhCDSCO lab Nov 2022
STN-181861Mfg 2019-03 · Exp 2021-02 Terrace Pharmaceuticals (P) Ltd. 3-B (a) Description and Related substancesDescription RDTL ChandigarhState lab Jan 2020

How to use this. Match the batch number on your strip or bottle against the list. If your batch is listed, return it to the pharmacy and ask for a replacement; if not, the product is not on any alert as of July 2026. Check any batch number.